TY - JOUR
T1 - Regenerative Engineering of Fibrotic Diseases
T2 - Mechanistic and Clinical Advances with Bone Marrow Mesenchymal Stem Cells
AU - Fuloria, Neeraj Kumar
AU - Fuloria, Shivkanya
AU - Sekar, Mahendran
AU - Porwal, Omji
AU - Ansari, Mohammed Tahir
AU - Biswas, Anupam
AU - Narain, Kamal
AU - Biswas, Sangita
AU - Bhatia, Sumita
AU - Murtey, Mogana Das
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to The Regenerative Engineering Society 2025.
PY - 2025/11/13
Y1 - 2025/11/13
N2 - Bone marrow-derived mesenchymal stem cells (BM-MSCs) have demonstrated significant potential owing to their strong immunomodulatory, anti-inflammatory, and regenerative properties. This review explores the antifibrotic effects of BM-MSCs, focusing on their underlying mechanisms, preclinical evidence, and progress in clinical trials. BM-MSCs moderate fibrosis through immune modulation, regulation of myofibroblast differentiation, and stimulation of matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix (ECM). In pulmonary fibrosis animal models, BM-MSCs reduced TGF-β1 activation and α-SMA and improved lung histology under experimental conditions; some studies included corticosteroid-treated comparators. Additionally, BM-MSCs inhibited the activation of hepatic stellate cells and promoted the polarization of macrophages to an M2 anti-inflammatory phenotype in liver fibrosis. Genetically modified bone marrow-derived mesenchymal stem cells (GM BM-MSCs), such as those transfected with miRNA or overexpressing IL-10, have demonstrated enhanced efficacy in ameliorating myocardial and renal fibrosis through increased homing, paracrine functions, and the inhibition of fibrosis-promoting genes. Early clinical trials of idiopathic pulmonary fibrosis and cirrhotic conditions have indicated their feasibility, safety, and potential efficacy. BM-MSC-derived extracellular vesicles (EVs) provide cell-free therapeutic alternatives with comparable benefits to those of BM-MSCs. Overall, this review provides a comprehensive mechanistic overview of the antifibrotic potential of BM-MSCs, highlighting their translational relevance across organ systems and their promise in regenerative medicine.
AB - Bone marrow-derived mesenchymal stem cells (BM-MSCs) have demonstrated significant potential owing to their strong immunomodulatory, anti-inflammatory, and regenerative properties. This review explores the antifibrotic effects of BM-MSCs, focusing on their underlying mechanisms, preclinical evidence, and progress in clinical trials. BM-MSCs moderate fibrosis through immune modulation, regulation of myofibroblast differentiation, and stimulation of matrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix (ECM). In pulmonary fibrosis animal models, BM-MSCs reduced TGF-β1 activation and α-SMA and improved lung histology under experimental conditions; some studies included corticosteroid-treated comparators. Additionally, BM-MSCs inhibited the activation of hepatic stellate cells and promoted the polarization of macrophages to an M2 anti-inflammatory phenotype in liver fibrosis. Genetically modified bone marrow-derived mesenchymal stem cells (GM BM-MSCs), such as those transfected with miRNA or overexpressing IL-10, have demonstrated enhanced efficacy in ameliorating myocardial and renal fibrosis through increased homing, paracrine functions, and the inhibition of fibrosis-promoting genes. Early clinical trials of idiopathic pulmonary fibrosis and cirrhotic conditions have indicated their feasibility, safety, and potential efficacy. BM-MSC-derived extracellular vesicles (EVs) provide cell-free therapeutic alternatives with comparable benefits to those of BM-MSCs. Overall, this review provides a comprehensive mechanistic overview of the antifibrotic potential of BM-MSCs, highlighting their translational relevance across organ systems and their promise in regenerative medicine.
KW - BM-MSCs
KW - Cardiac fibrosis
KW - Fibrosis
KW - Kidney fibrosis
KW - Liver fibrosis
KW - Lung fibrosis
UR - https://www.scopus.com/pages/publications/105021501733
U2 - 10.1007/s40883-025-00509-7
DO - 10.1007/s40883-025-00509-7
M3 - Review Article
AN - SCOPUS:105021501733
SN - 2364-4133
JO - Regenerative Engineering and Translational Medicine
JF - Regenerative Engineering and Translational Medicine
ER -